DEA Slaps Seven New Opioids into Ban List for Safety
Published Date: 6/26/2025
Proposed Rule
Summary
The DEA is temporarily putting seven new benzimidazole-opioids into Schedule I, meaning they’re now treated as highly controlled and illegal without special permission. This affects anyone who makes, sells, studies, or even holds these drugs, with strict rules and penalties kicking in right away. The move helps keep dangerous substances off the streets while the DEA finishes its full review.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Seven Benzimidazole-Opioids Placed in Schedule I
The DEA is temporarily placing seven benzimidazole-opioid substances into Schedule I of the Controlled Substances Act. When finalized, the Schedule I regulatory controls and the administrative, civil, and criminal sanctions that apply to Schedule I substances will apply to anyone who manufactures, distributes, reverse distributes, imports, exports, conducts research or instructional activities or chemical analysis, or possesses these seven substances.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-11711, Magnuson-Stevens Act Provisions; Fisheries of the Northeastern United States; Fisheries of the Northeastern United States; 2025-2027 Atlantic Herring Fishery Specifications
Starting in 2025, new fishing limits for Atlantic herring and river herring will help protect fish populations and support rebuilding efforts through 2027. These changes affect fishermen in the Northeastern U.S. and aim to keep fishing sustainable while meeting updated science goals. The plan updates when the herring stock should be fully rebuilt, ensuring a healthy fishery for the future.
Next: 2025-11737, Fisheries off West Coast States; Coastal Pelagic Species Fisheries; Annual Specifications; 2025-2026 Annual Specifications and Management Measures for Pacific Sardine
Starting July 1, 2025, most commercial fishing for Pacific sardines off Washington, Oregon, and California will be paused to help the sardine population bounce back. Fishermen can still catch sardines for live bait, small special fisheries, or as bycatch, but strict limits will keep the total catch low. This plan aims to protect the sardines while balancing fishing needs through June 30, 2026.